Article
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
American journal of clinical oncology - 1 Oct 2015
Lombardi Giuseppe, Rumiato Enrica, Bertorelle Roberta, Saggioro Daniela, Farina Patrizia, Della Puppa Alessandro, Zustovich Fable, Berti Franco, Sacchetto Valeria, Marcato Raffaella, Amadori Alberto, Zagonel Vittorina
Abstract excerpt
BACKGROUND: Temozolomide (TMZ) administered daily with radiation therapy (RT) for 6 weeks, followed by adjuvant TMZ for 6 cycles, is the standard therapy for newly diagnosed glioblastoma (GBM) patients. Although TMZ is considered to be a safe drug, it has been demonstrated to cause severe myelotoxicity; in particular, some case reports and small series studies have reported severe myelotoxicity developing during...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.